文献速递细菌感染、耐药与抗菌药物医院感染防控

万古霉素耐药屎肠球菌:入院时定植率、序列型及危险因素——2014至2018年德国七所大学医院的横断面研究

Vancomycin-resistant Enterococcus faecium: admission prevalence, sequence types and risk factors-a cross-sectional study in seven German university hospitals from 2014 to 2018.
PubMed 文献 · Clin Microbiol Infect · 2022-12-05

2014至2018年德国七所大学医院对入院72小时内患者筛查万古霉素耐药屎肠球菌(VREfm)并分析定植危险因素,17349例中265例定植,入院定植率1.5%,每年增加33%;危险因素包括年龄、既往或当前抗生素治疗、既往检出多重耐药菌、既往长期护理机构或医院住院及质子泵抑制剂/抗酸剂使用,ST117为新兴主要序列型。

要点

  • 入院VREfm定植率1.5%,每年增加33%,每增龄1岁增加2%。
  • 既往或当前抗生素治疗、既往多重耐药菌检出及既往住院是主要危险因素。
  • ST117占可基因分型VREfm的53.2%,为入院定植率上升的主要驱动序列型。

核心结论

  • 年龄、医疗接触及抗生素和质子泵抑制剂/抗酸剂使用增加个体VREfm定植风险,德国入院VREfm定植率上升主要由ST117出现驱动。

研究设计与样本

  • 2014至2018年在七所德国大学医院招募入院72小时内患者,筛查VREfm并问卷调查潜在危险因素,采用cgMLST进行基因分型,并行多变量分析。

主要发现

  • 17349例纳入患者中265例定植VREfm,入院定植率为1.5%。
  • 年龄aOR 1.02(95%CI 1.01-1.03),既往抗生素治疗aOR 2.71(95%CI 1.87-3.92),当前抗生素治疗aOR 2.91(95%CI 2.60-3.24)。
  • 既往检出多重耐药菌aOR 2.83(95%CI 2.21-3.63),既往长期护理机构停留aOR 2.19(95%CI 1.62-2.97),既往医院住院aOR 2.91(95%CI 2.05-4.13)。
  • 既往质子泵抑制剂/抗酸剂使用aOR 1.29(95%CI 1.18-1.41)。
  • VREfm入院定植率每年增加33%,每增龄1岁增加2%;265株中250株基因分型,141株(53.2%)为ST117。

关键数值与推荐

  • 多变量分析显示ST117与非ST117 VREfm定植患者在入院年份和既往多重耐药菌检出方面存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Assessment of vancomycin-resistant Enterococcus faecium (VREfm) prevalence upon hospital admission and analysis of risk factors for colonization. METHODS: From 2014 to 2018, patients were recruited within 72 hours of admission to seven participating German university hospitals, screened for VREfm and questioned for potential risk factors (prior multidrug-resistant organism detection, current/prior antibiotic consumption, prior hospital, rehabilitation or long-term care facility stay, international travel, animal contact and proton pump inhibitor [PPI]/antacid therapy). Genotype analysis was done using cgMLST typing. Multivariable analysis was performed. RESULTS: In 5 years, 265 of 17,349 included patients were colonized with VREfm (a prevalence of 1.5%). Risk factors for VREfm colonization were age (adjusted OR [aOR], 1.02; 95% CI, 1.01-1.03), previous (aOR, 2.71; 95% CI, 1.87-3.92) or current (aOR, 2.91; 95% CI, 2.60-3.24) antibiotic treatment, prior multidrug-resistant organism detection (aOR, 2.83; 95% CI, 2.21-3.63), prior stay in a long-term care facility (aOR, 2.19; 95% CI, 1.62-2.97), prior stay in a hospital (aOR, 2.91; 95% CI, 2.05-4.13) and prior consumption of PPI/antacids (aOR, 1.29; 95% CI, 1.18-1.41). Overall, the VREfm admission prevalence increased by 33% each year and 2% each year of life. 250 of 265 isolates were genotyped and 141 (53.2%) of the VREfm were the emerging ST117. Multivariable analysis showed that ST117 and non-ST117 VREfm colonized patients differed with respect to admission year and prior multidrug-resistant organism detection. DISCUSSION: Age, healthcare contacts and antibiotic and PPI/antacid consumption increase the individual risk of VREfm colonization. The VREfm admission prevalence increase in Germany is mainly driven by the emergence of ST117.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Rohde AM, Walker S, Behnke M, et al. Vancomycin-resistant Enterococcus faecium: admission prevalence, sequence types and risk factors-a cross-sectional study in seven German university hospitals from 2014 to 2018. Clin Microbiol Infect. 2022. PMID: 36481293. doi:10.1016/j.cmi.2022.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。